Yorktown Management & Research Co Inc Raises Stock Position in Insmed, Inc. $INSM

by · The Markets Daily

Yorktown Management & Research Co Inc raised its holdings in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 64.1% during the third quarter, HoldingsChannel reports. The firm owned 9,600 shares of the biopharmaceutical company’s stock after purchasing an additional 3,750 shares during the period. Insmed comprises 1.1% of Yorktown Management & Research Co Inc’s portfolio, making the stock its 14th largest holding. Yorktown Management & Research Co Inc’s holdings in Insmed were worth $1,382,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Spire Wealth Management raised its stake in shares of Insmed by 11.5% during the 3rd quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 80 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in Insmed by 59.6% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 81 shares in the last quarter. Moody Aldrich Partners LLC increased its stake in shares of Insmed by 2.4% in the 3rd quarter. Moody Aldrich Partners LLC now owns 5,551 shares of the biopharmaceutical company’s stock worth $799,000 after acquiring an additional 132 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in Insmed by 24.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 186 shares during the last quarter. Finally, Yousif Capital Management LLC increased its position in shares of Insmed by 9.3% during the 3rd quarter. Yousif Capital Management LLC now owns 2,188 shares of the biopharmaceutical company’s stock worth $315,000 after purchasing an additional 187 shares during the last quarter.

Insider Transactions at Insmed

In related news, insider Michael Alexander Smith sold 1,053 shares of the company’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $174.17, for a total transaction of $183,401.01. Following the transaction, the insider owned 57,037 shares in the company, valued at $9,934,134.29. This represents a 1.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO William Lewis sold 19,215 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the completion of the transaction, the chief executive officer directly owned 306,891 shares in the company, valued at $51,864,579. This trade represents a 5.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 286,100 shares of company stock worth $52,595,894 over the last quarter. 3.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

INSM has been the topic of several recent research reports. Bank of America upped their target price on shares of Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. UBS Group lowered their target price on shares of Insmed from $223.00 to $215.00 and set a “buy” rating on the stock in a research report on Tuesday, January 6th. Royal Bank Of Canada cut their price objective on shares of Insmed from $215.00 to $195.00 and set an “outperform” rating for the company in a research report on Thursday, December 18th. Evercore ISI reiterated an “outperform” rating and issued a $180.00 price target on shares of Insmed in a report on Wednesday, October 1st. Finally, Guggenheim dropped their price objective on Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Insmed currently has a consensus rating of “Moderate Buy” and a consensus target price of $205.77.

Read Our Latest Analysis on Insmed

Insmed Trading Up 1.3%

Shares of NASDAQ:INSM opened at $161.42 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $212.75. The stock has a market capitalization of $34.43 billion, a price-to-earnings ratio of -26.08 and a beta of 1.08. The company has a 50 day moving average price of $187.73 and a 200 day moving average price of $154.36.

Insmed (NASDAQ:INSM – Get Free Report) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The firm had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. During the same quarter last year, the firm earned ($1.27) EPS. The business’s revenue for the quarter was up 52.4% compared to the same quarter last year. On average, research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Company Profile

(Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

Featured Articles

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM – Free Report).